Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC’s) approval of PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab). This approval authorizes the use of this combination therapy as a first-line treatment for adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-based chemotherapy. A New […]
Everest Medicines Limited (HKEX: 1952.HK) has announced the launch of an Investigator-Initiated Clinical Trial (IIT) for its innovative personalized mRNA cancer vaccine, EVM16. The trial, designated EVM16CX01, is set to take place at Peking University Cancer Hospital and Fudan University’s Cancer Hospital. This groundbreaking study will be the first-in-human (FIH) trial for EVM16, designed to […]
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.’s shareholders have overwhelmingly voted in favor of the proposed acquisition by AstraZeneca. During a special virtual meeting, approximately 80.83% of Fusion’s issued and outstanding shares were represented, with 99.92% of these votes endorsing the acquisition under the terms of a plan of arrangement as […]